A. Zuardi

发表

Lipoma adhered to the corpus callosum in a schizophrenic patient with severe positive symptoms that responded to clozapine

J. Crippa, J. Hallak, R. Sanches, 2002, Acta Neuropsychiatrica.

Rapid improvement of acute schizophrenia symptoms after intravenous sodium nitroprusside: a randomized, double-blind, placebo-controlled trial.

S. Dursun, J. Crippa, A. Zuardi, 2013, JAMA psychiatry.

Distinct effects of {delta}9-tetrahydrocannabinol and cannabidiol on neural activation during emotional processing.

P. McGuire, S. Surguladze, P. Allen, 2009, Archives of general psychiatry.

Alcohol Use Disorders Identification Test (AUDIT): an updated systematic review of psychometric properties

J. Crippa, A. Zuardi, S. Loureiro, 2009 .

Is cannabidiol the ideal drug to treat non-motor Parkinson’s disease symptoms?

F. Guimarães, J. Crippa, J. Hallak, 2019, European Archives of Psychiatry and Clinical Neuroscience.

Patterns of regional gray matter loss at different stages of schizophrenia: A multisite, cross-sectional VBM study in first-episode and chronic illness☆

Wagner F. Gattaz, Robin M. Murray, Geraldo F. Busatto, 2016, NeuroImage: Clinical.

Evaluation of the role of the cannabidiol system in an animal model of ischemia/reperfusion kidney injury

F. Dal-Pizzol, J. Hallak, J. Crippa, 2015, Revista Brasileira de terapia intensiva.

Endocannabinoid System Attenuates Oxaliplatin-Induced Peripheral Sensory Neuropathy Through the Activation of CB1 Receptors

A. R. de Oliveira, J. Crippa, J. Hallak, 2021, Neurotoxicity Research.

Effects of acute cannabidiol administration on anxiety and tremors induced by a Simulated Public Speaking Test in patients with Parkinson’s disease

P. C. Castro, J. Crippa, A. Zuardi, 2020, Journal of psychopharmacology.

Cavum septum pellucidum and adhesio interthalamica in schizophrenia: an MRI study

P. McGuire, E. Amaro, V. Ng, 2006, European Psychiatry.

Is the highest density of CB1 receptors in paranoid schizophrenia a correlate of endocannabinoid system functioning?

J. Hallak, J. Crippa, A. Zuardi, 2011, Expert review of neurotherapeutics.

Impact of length of stay for first psychiatric admissions on the ratio of readmissions in subsequent years in a large Brazilian catchment area

A. Zuardi, C. Del-Ben, J. Santos, 2016, Social Psychiatry and Psychiatric Epidemiology.

Characteristics of the stimulus produced by the mixture of cannabidiol with delta 9-tetrahydrocannabinol.

A. Zuardi, R. Musty, O. F. Bueno, 1981, Archives internationales de pharmacodynamie et de therapie.

Modulation of effective connectivity during emotional processing by Delta 9-tetrahydrocannabinol and cannabidiol.

A. Mechelli, P. McGuire, P. Allen, 2010, The international journal of neuropsychopharmacology.

Antidepressant-like and anxiolytic-like effects of cannabidiol: a chemical compound of Cannabis sativa.

O. Arias-Carrión, S. Machado, A. Nardi, 2014, CNS & neurological disorders drug targets.

Effects of Cannabidiol (CBD) on Regional Cerebral Blood Flow

P. McGuire, G. Busatto, J. Hallak, 2004, Neuropsychopharmacology.

Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug.

F. Guimarães, J. Crippa, J. Hallak, 2006, Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas.

Memory-rescuing effects of cannabidiol in an animal model of cognitive impairment relevant to neurodegenerative disorders

N. Schröder, J. Crippa, A. Zuardi, 2011, Psychopharmacology.

Interaction between cannabidiol (CBD) and ∆9-tetrahydrocannabinol (THC): influence of administration interval and dose ratio between the cannabinoids

J. Crippa, J. Hallak, A. Zuardi, 2011, Psychopharmacology.

Impact of different approaches of primary care mental health on the prevalence of mental disorders

A. Zuardi, A. L. Rodrigues-Junior, L. Moscovici, 2017, Primary Health Care Research & Development.

Is the full version of the AUDIT really necessary? Study of the validity and internal construct of its abbreviated versions.

J. Hallak, J. Crippa, A. Zuardi, 2010, Alcoholism, clinical and experimental research.

Induction of psychosis by Δ9-tetrahydrocannabinol reflects modulation of prefrontal and striatal function during attentional salience processing.

P. McGuire, M. Brammer, V. Giampietro, 2012, Archives of general psychiatry.

Potential cannabidiol (CBD) repurposing as antibacterial and promising therapy of CBD plus polymyxin B (PB) against PB-resistant gram-negative bacilli

A. Zuardi, F. Pavan, R. Cantón, 2022, Scientific Reports.

Effects of minocycline add-on treatment on brain morphometry and cerebral perfusion in recent-onset schizophrenia

S. Dursun, F. Guimarães, R. Bressan, 2015, Schizophrenia Research.

Cannabidiol: from an inactive cannabinoid to a drug with wide spectrum of action.

A. Zuardi, 2008, Revista brasileira de psiquiatria.

History of cannabis as a medicine: a review.

A. Zuardi, 2006, Revista brasileira de psiquiatria.

Cannabidiol, a Cannabis sativa constituent, as an anxiolytic drug.

Natalia Pinho de Oliveira Ribeiro, A. Nardi, J. Crippa, 2012, Revista brasileira de psiquiatria.

Cannabidiol reverses memory impairments and activates components of the Akt/GSK3β pathway in an experimental model of estrogen depletion

N. Schröder, J. Crippa, A. Zuardi, 2021, Behavioural Brain Research.

Administration of Harmine and Imipramine Alters Creatine Kinase and Mitochondrial Respiratory Chain Activities in the Rat Brain

G. Réus, J. Quevedo, J. Hallak, 2011, Depression research and treatment.

Cannabidiol as a Treatment for Mental Health Outcomes Among Health Care Workers During the Coronavirus Disease Pandemic

F. Guimarães, J. Crippa, J. Hallak, 2021, Journal of clinical psychopharmacology.

Cannabidiol as an add-on therapy to overcome the slow-onset and, possibly, resistance to antidepressant treatment: involvement of NAPE-PLD in the medial prefrontal cortex

K. Mackie, F. Guimarães, C. Sorgi, 2021, bioRxiv.

Cannabis affects people differently: inter-subject variation in the psychotogenic effects of Δ9-tetrahydrocannabinol: a functional magnetic resonance imaging study with healthy volunteers

P. Mcguire, P. Allen, D. Ståhl, 2012, Psychological Medicine.

Cannabidiol did not induce teratogenicity or neurotoxicity in exposed zebrafish embryos.

J. Hallak, J. Crippa, A. Zuardi, 2018, Chemico-biological interactions.

Cannabidiol for Rapid Eye Movement Sleep Behavior Disorder

J. Hallak, J. Crippa, A. Zuardi, 2021, Movement disorders : official journal of the Movement Disorder Society.

Cannabidiol can improve complex sleep‐related behaviours associated with rapid eye movement sleep behaviour disorder in Parkinson's disease patients: a case series

J. Crippa, A. Zuardi, C. Schenck, 2014, Journal of clinical pharmacy and therapeutics.

Reduction of the anxiety of medical students after curricular reform.

A. Zuardi, C. Del-Ben, Fernando Del Guerra Prota, 2008, Revista brasileira de psiquiatria.

Antiapoptotic effects of cannabidiol in an experimental model of cognitive decline induced by brain iron overload

N. Schröder, J. Hallak, J. Crippa, 2018, Translational Psychiatry.

Novel insights into mitochondrial molecular targets of iron-induced neurodegeneration: Reversal by cannabidiol

N. Schröder, J. Hallak, J. Crippa, 2018, Brain Research Bulletin.

Cannabidiol reduces airway inflammation and fibrosis in experimental allergic asthma

F. Dal-Pizzol, J. Crippa, A. Zuardi, 2019, European journal of pharmacology.

Functional neuroimaging of minocycline's effect in a patient with schizophrenia

S. Dursun, J. Hallak, J. Crippa, 2010, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

Cannabidiol for the Treatment of Drug Use Disorders

J. Hallak, A. Zuardi, J. Crippa, 2017 .

Serious adverse effects of cannabidiol (CBD): a review of randomized controlled trials

F. Guimarães, J. Hallak, J. Crippa, 2020, Expert opinion on drug metabolism & toxicology.

Antipsychotic effect of cannabidiol.

F. Guimarães, A. Zuardi, R. Mechoulam, 1995, The Journal of clinical psychiatry.

Cannabidiol for the treatment of autism spectrum disorder: hope or hype?

F. Guimarães, A. Zuardi, Jaime E. C. Hallak, 2022, Psychopharmacology.

Cannabinoids modulate proliferation, differentiation, and migration signaling pathways in oligodendrocytes

D. Martins‐de‐Souza, A. Zuardi, M. Fioramonte, 2022, European Archives of Psychiatry and Clinical Neuroscience.

Reliability of the Portuguese version of the structured clinical interview for DSM-III-R (SCID) in a Brazilian sample of psychiatric outpatients.

A. Zuardi, C. Del-Ben, C. R. Rodrigues, 1996, Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas.

Cannabinoid-Based Therapies and Brain Development: Potential Harmful Effect of Early Modulation of the Endocannabinoid System

I. J. Bristot, F. Klamt, J. Hallak, 2018, CNS Drugs.

Cannabidiol attenuates mechanical allodynia in streptozotocin-induced diabetic rats via serotonergic system activation through 5-HT1A receptors

J. Hallak, J. Crippa, A. Zuardi, 2019, Brain Research.

Efficacy and Safety of Cannabidiol Plus Standard Care vs Standard Care Alone for the Treatment of Emotional Exhaustion and Burnout Among Frontline Health Care Workers During the COVID-19 Pandemic

F. Guimarães, S. Sen, J. Crippa, 2021, JAMA network open.

A Conversion of Oral Cannabidiol to Delta9-Tetrahydrocannabinol Seems Not to Occur in Humans

G. Nahler, A. Zuardi, F. Grotenhermen, 2017, Cannabis and cannabinoid research.

Cannabidiol for COVID-19 Patients with Mild to Moderate Symptoms (CANDIDATE Study): A Randomized, Double-Blind, Placebo-Controlled Clinical Trial.

F. Guimarães, J. Crippa, A. Zuardi, 2021, Cannabis and cannabinoid research.

Peripubertal treatment with cannabidiol prevents the emergence of psychosis in an animal model of schizophrenia

R. Bressan, A. Zuardi, J. Crippa, 2016, Schizophrenia Research.

Cannabidiol exhibits anxiolytic but not antipsychotic property evaluated in the social interaction test

J. Crippa, A. Zuardi, Jaime E. C. Hallak, 2013, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

Marijuana, feijoada and the debate on drug legalization

J. Hallak, A. Zuardi, J. Crippa, 2013, Front. Psychiatry.

Workplace Protections and Burnout Among Brazilian Frontline Health Care Professionals During the COVID-19 Pandemic

J. Crippa, J. Hallak, A. Zuardi, 2022, Frontiers in Psychology.

Cannabidiol, a non-psychotropic plant-derived cannabinoid, decreases inflammation in a murine model of acute lung injury: role for the adenosine A(2A) receptor.

J. Quevedo, F. Dal-Pizzol, J. Hallak, 2012, European journal of pharmacology.

The Fast Alcohol Screening Test (FAST) is as Good as the AUDIT to Screen Alcohol Use Disorders

R. Martín-Santos, J. Hallak, J. Crippa, 2010, Substance use & misuse.

[Therapeutical use of the cannabinoids in psychiatry].

J. Hallak, J. Crippa, A. Zuardi, 2010, Revista brasileira de psiquiatria.

Glutamate-N-methyl-D-aspartate receptor modulation and minocycline for the treatment of patients with schizophrenia: an update.

S. Dursun, J. Crippa, A. Zuardi, 2009, Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas.

Acute harmine administration induces antidepressive-like effects and increases BDNF levels in the rat hippocampus

G. Réus, J. Quevedo, J. Hallak, 2009, Progress in Neuro-psychopharmacology and Biological Psychiatry.

Pharmacological interventions in the treatment of the acute effects of cannabis: a systematic review of literature

R. Martín-Santos, Z. Atakan, A. Zuardi, 2012, Harm Reduction Journal.

A. Zuardi, 1990, Neuroscience & Biobehavioral Reviews.

Cannabidiol for the Treatment of Epilepsy: An Overview of Possible Mechanisms of Action and Preclinical and Human Studies

J. Hallak, A. Zuardi, J. Crippa, 2017 .

Phytocannabinoids and epilepsy

J. Crippa, A. Zuardi, J. Hallak, 2015, Journal of clinical pharmacy and therapeutics.

Cannabidiol increases Fos expression in the nucleus accumbens but not in the dorsal striatum.

F. Guimarães, A. Zuardi, E. D. Del Bel, 2004, Life sciences.

Cannabidiol monotherapy for treatment-resistant schizophrenia

S. Dursun, J. Crippa, J. Hallak, 2006, Journal of psychopharmacology.

Cannabidiol and Sodium Nitroprusside: Two Novel Neuromodulatory Pharmacological Interventions to Treat and Prevent Psychosis.

J. Crippa, J. Hallak, A. Zuardi, 2015, CNS & neurological disorders drug targets.

[Brain effects of cannabis--neuroimaging findings].

E. Amaro, R. Bressan, J. Crippa, 2005, Revista brasileira de psiquiatria.

Duloxetine in the treatment of panic disorder.

J. Crippa, A. Zuardi, 2006, The international journal of neuropsychopharmacology.

Changes in Cortisol Awakening Response Before and After Development of Posttraumatic Stress Disorder, Which Cannot be Avoided with Use of Cannabidiol: A Case Report.

J. Crippa, A. Zuardi, M. de Castro, 2019, The Permanente journal.

Effects of cannabidiol on symptoms induced by the recall of traumatic events in patients with posttraumatic stress disorder

F. Guimarães, J. Hallak, A. Zuardi, 2022, Psychopharmacology.

Pharmacological interaction of the effects of delta 9-trans-tetrahydrocannabinol and cannabidiol on serum corticosterone levels in rats.

A. Zuardi, N. Teixeira, I. C. Karniol, 1984, Archives internationales de pharmacodynamie et de therapie.

Effects of acute systemic administration of cannabidiol on sleep-wake cycle in rats

S. Tufik, J. Crippa, A. Zuardi, 2013, Journal of psychopharmacology.

Performance of schizophrenic patients in the Stroop Color Word Test and electrodermal responsiveness after acute administration of cannabidiol (CBD).

J. Hallak, J. Crippa, R. Sanches, 2010, Revista brasileira de psiquiatria.

Role of the endocannabinoid and endovanilloid systems in an animal model of schizophrenia-related emotional processing/cognitive deficit

J. Crippa, J. Hallak, A. Zuardi, 2019, Neuropharmacology.

Effects of cannabinoid and vanilloid drugs on positive and negative-like symptoms on an animal model of schizophrenia: The SHR strain

A. Zuardi, J. Crippa, Jaime E. C. Hallak, 2014, Schizophrenia Research.

Cannabidiol presents an inverted U-shaped dose-response curve in a simulated public speaking test

F. Guimarães, J. Crippa, A. Zuardi, 2018, Revista brasileira de psiquiatria.

Translational Investigation of the Therapeutic Potential of Cannabidiol (CBD): Toward a New Age

F. Guimarães, A. Zuardi, A. Campos, 2018, Front. Immunol..

No Acute Effects of Cannabidiol on the Sleep-Wake Cycle of Healthy Subjects: A Randomized, Double-Blind, Placebo-Controlled, Crossover Study

F. Guimarães, J. Crippa, A. Zuardi, 2018, Front. Pharmacol..

Effects of cannabidiol in the treatment of patients with Parkinson’s disease: An exploratory double-blind trial

J. Crippa, A. Zuardi, M. H. Chagas, 2014, Journal of psychopharmacology.

Cannabidiol Reduces the Anxiety Induced by Simulated Public Speaking in Treatment-Naïve Social Phobia Patients

Marcos Hortes Nisihara Chagas, Flávio Kapczinski, Antonio E Nardi, 2011, Neuropsychopharmacology.

Effect of cannabidiol on plasma prolactin, growth hormone and cortisol in human volunteers.

F. Guimarães, A. Zuardi, A. Moreira, 1993, Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas.

Action of cannabidiol on the anxiety and other effects produced by delta 9-THC in normal subjects.

A. Zuardi, I. G. Karniol, E. Finkelfarb, 1982, Psychopharmacology.

P.1.g.022 Opposite effects of THC and CBD on auditory mismatch negativity: a randomised controlled trial of acute cannabinoid administration

R. Croft, P. Michie, N. Solowij, 2014, European Neuropsychopharmacology.

Inverted U-Shaped Dose-Response Curve of the Anxiolytic Effect of Cannabidiol during Public Speaking in Real Life

F. Guimarães, J. Hallak, J. Crippa, 2017, Front. Pharmacol..

Treatment with cannabidiol reverses oxidative stress parameters, cognitive impairment and mortality in rats submitted to sepsis by cecal ligation and puncture

J. Quevedo, F. Dal-Pizzol, F. Petronilho, 2010, Brain Research.

Maternal administration of cannabidiol promotes an anti-inflammatory effect on the intestinal wall in a gastroschisis rat model

J. Crippa, A. Zuardi, L. Sbragia, 2018, Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas.

Effects of cannabidiol in animal models predictive of antipsychotic activity

A. Zuardi, J. ANTUNES RODRIGUES, J. A. Rodrigues, 2005, Psychopharmacology.

Psychometric qualities of the Brazilian versions of the Fagerström Test for Nicotine Dependence and the Heaviness of Smoking Index.

J. Crippa, A. Zuardi, S. Loureiro, 2009, Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco.

Psychometric properties of the Fagerström Test for Nicotine Dependence.

J. Crippa, A. Zuardi, S. Loureiro, 2009, Jornal brasileiro de pneumologia : publicacao oficial da Sociedade Brasileira de Pneumologia e Tisilogia.

Immunopharmacology and inflammation Cannabidiol reduces host immune response and prevents cognitive impairments in Wistar rats submitted to pneumococcal meningitis

J. Quevedo, J. Crippa, A. Zuardi, 2012 .

Action of cannabidiol on the anxiety and other effects produced by δ9-THC in normal subjects

A. Zuardi, I. G. Karniol, E. Finkelfarb, 2004, Psychopharmacology.

Antidepressive, anxiolytic, and antiaddictive effects of ayahuasca, psilocybin and lysergic acid diethylamide (LSD): a systematic review of clinical trials published in the last 25 years

J. Riba, J. Crippa, J. Hallak, 2016, Therapeutic advances in psychopharmacology.

Cannabidiol effectively reverses mechanical and thermal allodynia, hyperalgesia, and anxious behaviors in a neuropathic pain model: Possible role of CB1 and TRPV1 receptors

J. Crippa, A. Zuardi, N. Garcia-Cairasco, 2021, Neuropharmacology.

Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder: a preliminary report

P. McGuire, G. Busatto, P. Fusar-Poli, 2011, Journal of psychopharmacology.

Intra-dorsal periaqueductal gray administration of cannabidiol blocks panic-like response by activating 5-HT1A receptors

F. Guimarães, A. Zuardi, A. Campos, 2010, Behavioural Brain Research.

Acute effects of a single, oral dose of d9-tetrahydrocannabinol (THC) and cannabidiol (CBD) administration in healthy volunteers.

P. McGuire, P. Allen, S. Borgwardt, 2012, Current pharmaceutical design.

Opposite Effects of Δ-9-Tetrahydrocannabinol and Cannabidiol on Human Brain Function and Psychopathology

R. Murray, S. Kapur, P. McGuire, 2010, Neuropsychopharmacology.

Sex-dependent differences in the anxiolytic-like effect of cannabidiol in the elevated plus-maze

T. Lovick, M. Brandão, A. Zuardi, 2022, Journal of psychopharmacology.

Safety and side effects of cannabidiol, a Cannabis sativa constituent.

J. Crippa, A. Zuardi, R. Queiroz, 2011, Current drug safety.

The interplay of cannabinoid and NMDA glutamate receptor systems in humans: Preliminary evidence of interactive effects of cannabidiol and ketamine in healthy human subjects

P. Mcguire, J. Krystal, S. Dursun, 2011, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

Biological bases for a possible effect of cannabidiol in Parkinson’s disease

F. Guimarães, J. Crippa, A. Zuardi, 2019, Revista brasileira de psiquiatria.

Protective Effects of Cannabidiol against Seizures and Neuronal Death in a Rat Model of Mesial Temporal Lobe Epilepsy

J. Hallak, J. Crippa, A. Zuardi, 2017, Front. Pharmacol..

Cannabidiol Prevents Motor and Cognitive Impairments Induced by Reserpine in Rats

J. Hallak, J. Crippa, A. Zuardi, 2016, Front. Pharmacol..

Modulation of Auditory and Visual Processing by Delta-9-Tetrahydrocannabinol and Cannabidiol: an fMRI Study

Paul Allen, Paolo Fusar-Poli, Marc L Seal, 2010, Neuropsychopharmacology.

Is Cannabidiol During Neurodevelopment a Promising Therapy for Schizophrenia and Autism Spectrum Disorders?

J. Hallak, J. Crippa, A. Zuardi, 2021, Frontiers in Pharmacology.

A critical review of the antipsychotic effects of cannabidiol: 30 years of a translational investigation.

P. McGuire, F. Guimarães, R. Martín-Santos, 2012, Current pharmaceutical design.

Serotonin mediates the panicolytic-like effect of oxytocin in the dorsal periaqueductal gray

A. Zuardi, H. Zangrossi, Thatiane de Oliveira Sergio, 2020, Journal of psychopharmacology.

Selective post-training time window for memory consolidation interference of cannabidiol into the prefrontal cortex: Reduced dopaminergic modulation and immediate gene expression in limbic circuits

J. Crippa, A. Zuardi, J. E. Peixoto-Santos, 2017, Neuroscience.

Harmine and Imipramine Promote Antioxidant Activities in Prefrontal Cortex and Hippocampus

G. Réus, J. Quevedo, F. Dal-Pizzol, 2010, Oxidative medicine and cellular longevity.

Diagnostic profile of inpatients as a determinant of length of stay in a general hospital psychiatric unit.

A. Zuardi, J. Crippa, J. Hallak, 2003, Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas.

A False Case of Clozapine-Resistant Schizophrenia

A. Sakamoto, A. Zuardi, J. P. MACHADO-DE-SOUSA, 2010, Case reports in medicine.

Interictal SPECT in patients with mesial temporal lobe epilepsy and psychosis: a case-control study

J. Deakin, M. Bianchin, A. Sakamoto, 2005, Psychiatry Research: Neuroimaging.

Short admission in an emergency psychiatry unit can prevent prolonged lengths of stay in a psychiatric institution.

A. Zuardi, C. Del-Ben, R. E. M. Barros, 2009, Revista brasileira de psiquiatria.

Δ 9 -Tetrahydrocannabinol alone and combined with cannabidiol mitigate fear memory through reconsolidation disruption

F. Guimarães, I. Galve-Roperh, A. Zuardi, 2015, European Neuropsychopharmacology.

Acute and chronic administration of cannabidiol increases mitochondrial complex and creatine kinase activity in the rat brain.

J. Quevedo, J. Hallak, J. Crippa, 2013, Revista brasileira de psiquiatria.

Is the Fagerström Test for Nicotine Dependence a good instrument to assess tobacco use in patients with schizophrenia?

J. Crippa, A. Zuardi, S. Loureiro, 2009, Revista brasileira de psiquiatria.

Effects of cannabidiol on amphetamine-induced oxidative stress generation in an animal model of mania

S. Dursun, J. Quevedo, F. Dal-Pizzol, 2011, Journal of psychopharmacology.

Antipsychotic profile of cannabidiol and rimonabant in an animal model of emotional context processing in schizophrenia.

J. Hallak, J. Crippa, A. Zuardi, 2012, Current pharmaceutical design.

Antianxiety effect of cannabidiol in the elevated plus-maze

F. Graeff, F. Guimarães, A. Zuardi, 2005, Psychopharmacology.

Proton magnetic resonance spectroscopy of the frontal, cingulate and perirolandic cortices and its relationship to skin conductance in patients with schizophrenia.

D. Araujo, J. Crippa, R. Sanches, 2008, Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas.

Electrodermically nonresponsive schizophrenia patients make more errors in the Stroop Color Word Test, indicating selective attention deficit.

F. Guimarães, J. Hallak, A. Zuardi, 2002, Schizophrenia bulletin.

Are cavum septum pellucidum abnormalities more common in schizophrenia spectrum disorders? A systematic review and meta-analysis

P. Mcguire, G. Busatto, M. Kempton, 2011, Schizophrenia Research.

Adhesio interthalamica alterations in schizophrenia spectrum disorders: A systematic review and meta-analysis

P. Mcguire, G. Busatto, M. Kempton, 2011, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

Cannabidiol, among Other Cannabinoid Drugs, Modulates Prepulse Inhibition of Startle in the SHR Animal Model: Implications for Schizophrenia Pharmacotherapy

J. Hallak, J. Crippa, A. Zuardi, 2016, Front. Pharmacol..

Effects of cannabinoid drugs on the deficit of prepulse inhibition of startle in an animal model of schizophrenia: the SHR strain

J. Hallak, J. Crippa, A. Zuardi, 2014, Front. Pharmacol..

Treatment of of koro with citalopram.

A. Zuardi, J. Crippa, J. Hallak, 2000, The Journal of clinical psychiatry.

Risk and Protective Factors for the Mental Health of Brazilian Healthcare Workers in the Frontline of COVID-19 Pandemic

J. Hallak, J. Crippa, A. Zuardi, 2021, Frontiers in Psychiatry.

Oral Cannabidiol Does Not Convert to Δ8-THC or Δ9-THC in Humans: A Pharmacokinetic Study in Healthy Subjects.

F. Guimarães, J. Crippa, J. Hallak, 2020, Cannabis and Cannabinoid Research.

Even High Doses of Oral Cannabidiol Do Not Cause THC-Like Effects in Humans: Comment on Merrick et al. Cannabis and Cannabinoid Research 2016;1(1):102–112; DOI: 10.1089/can.2015.0004

A. Zuardi, F. Grotenhermen, Ethan B. Russo, 2017, Cannabis and cannabinoid research.

Δ9-THC Intoxication by Cannabidiol-Enriched Cannabis Extract in Two Children with Refractory Epilepsy: Full Remission after Switching to Purified Cannabidiol

R. Martín-Santos, J. Hallak, A. Zuardi, 2016, Front. Pharmacol..

Clozapine monotherapy for catatonic schizophrenia: should clozapine be the treatment of choice, with catatonia rather than psychosis as the main therapeutic index?

J. Deakin, S. Dursun, I. Anderson, 2005, Journal of psychopharmacology.

Electroconvulsive therapy for coexistent schizophrenia and obsessive-compulsive disorder.

J. Crippa, A. Zuardi, S. L. Morais, 2005, The Journal of clinical psychiatry.

Social anxiety disorder women easily recognize fearfull, sad and happy faces: the influence of gender.

A. Nardi, L. Hetem, J. Hallak, 2010, Journal of psychiatric research.

Caffeine protects against memory loss induced by high and non-anxiolytic dose of cannabidiol in adult zebrafish (Danio rerio)

J. Hallak, J. Crippa, A. Zuardi, 2015, Pharmacology Biochemistry and Behavior.

Cannabidiol induces autophagy via ERK1/2 activation in neural cells

S. Smaili, G. Pereira, C. Bincoletto, 2021, Scientific Reports.

Cannabidiol for the treatment of cannabis withdrawal syndrome: a case report

A. Zuardi, J. P. MACHADO-DE-SOUSA, J. Crippa, 2013, Journal of clinical pharmacy and therapeutics.

Interaction between cannabidiol (CBD) and ∆9-tetrahydrocannabinol (THC): influence of administration interval and dose ratio between the cannabinoids

J. Crippa, J. Hallak, A. Zuardi, 2011, Psychopharmacology.

Dissociation between the panicolytic effect of cannabidiol microinjected into the substantia nigra, pars reticulata, and fear-induced antinociception elicited by bicuculline administration in deep layers of the superior colliculus: The role of CB1-cannabinoid receptor in the ventral mesencephalon.

A. Zuardi, N. Coimbra, R. C. Almada, 2015, European journal of pharmacology.

Cannabis and anxiety: a critical review of the evidence

P. McGuire, P. Fusar-Poli, R. Martín-Santos, 2009, Human psychopharmacology.

Cannabidiol Is a Potential Therapeutic for the Affective-Motivational Dimension of Incision Pain in Rats

J. Crippa, A. Zuardi, W. A. Prado, 2017, Front. Pharmacol..

The Anxiolytic Effects of Cannabidiol (CBD)

F. Guimarães, A. Zuardi, J. Crippa, 2017 .

Involvement of serotonin-mediated neurotransmission in the dorsal periaqueductal gray matter on cannabidiol chronic effects in panic-like responses in rats

F. Guimarães, M. Brandão, A. Zuardi, 2013, Psychopharmacology.

Anti-Aversive Effects of Cannabidiol on Innate Fear-Induced Behaviors Evoked by an Ethological Model of Panic Attacks Based on a Prey vs the Wild Snake Epicrates cenchria crassus Confrontation Paradigm

J. Crippa, J. Hallak, A. Zuardi, 2012, Neuropsychopharmacology.

Method for evaluating subjective states of awareness that accompany recognition: adaptation for use in Portuguese-speaking patients with schizophrenia.

A. Zuardi, L. Hetem, Marcos Aurélio Martins Ribeiro, 2005, Revista brasileira de psiquiatria.

Evaluation of Serum Cytokines Levels and the Role of Cannabidiol Treatment in Animal Model of Asthma

F. Dal-Pizzol, F. Petronilho, J. Crippa, 2015, Mediators of inflammation.

Cannabidiol for the treatment of crack-cocaine craving: an exploratory double-blind study

R. Laranjeira, R. Bressan, J. Hallak, 2020, Revista brasileira de psiquiatria.

Effect of metergoline on human anxiety

F. Graeff, A. Zuardi, E. C. Lima Filho, 2004, Psychopharmacology.

Rimonabant effects on anxiety induced by simulated public speaking in healthy humans: a preliminary report

M. Huestis, A. Nardi, J. Crippa, 2014, Human psychopharmacology.

Minocycline as a potential treatment in the early stages of schizophrenia: a translational approach

J. Hallak, A. Zuardi, C. Chaves, 2015 .

COOP/WONCA Charts as a Screen for Mental Disorders in Primary Care

A. Zuardi, Antonio Waldo Zuardi, Joao Mazzoncini de Azevedo-Marques, 2011, The Annals of Family Medicine.

Validity and applicability of the Mini International Neuropsychiatric Interview administered by family medicine residents in primary health care in Brazil.

A. Zuardi, J. M. de Azevedo Marques, 2008, General hospital psychiatry.

Burden and Stress Among Psychiatry Residents and Psychiatric Healthcare Providers

A. Zuardi, M. Bandeira, S. Ishara, 2011, Academic psychiatry : the journal of the American Association of Directors of Psychiatric Residency Training and the Association for Academic Psychiatry.

Oxytocin interference in the effects induced by inhalation of 7.5% CO2 in healthy volunteers

J. Crippa, A. Zuardi, M. H. Chagas, 2012, Human psychopharmacology.

Anxiolytic-like effect of oxytocin in the simulated public speaking test

F. Graeff, J. Crippa, A. Zuardi, 2012, Journal of psychopharmacology.

Chronic administration of harmine elicits antidepressant-like effects and increases BDNF levels in rat hippocampus

G. Réus, J. Quevedo, J. Hallak, 2010, Journal of Neural Transmission.

Cannabidiol Administered During Peri-Adolescence Prevents Behavioral Abnormalities in an Animal Model of Schizophrenia

J. Hallak, J. Crippa, A. Zuardi, 2018, Front. Pharmacol..

Modulation of Auditory and Visual Processing by Delta-9-Tetrahydrocannabinol and Cannabidiol: an fMRI Study

Paul Allen, Paolo Fusar-Poli, Marc L Seal, 2011, Neuropsychopharmacology.

Administration of cannabidiol and imipramine induces antidepressant-like effects in the forced swimming test and increases brain-derived neurotrophic factor levels in the rat amygdala

H. Abelaira, G. Réus, J. Quevedo, 2011, Acta Neuropsychiatrica.

Effects of β-carboline harmine on behavioral and physiological parameters observed in the chronic mild stress model: Further evidence of antidepressant properties

G. Réus, J. Quevedo, J. Crippa, 2010, Brain Research Bulletin.

Cannabidiol (CBD) repurposing as antibacterial: promising therapy of CBD plus polymyxin B against superbugs

A. Zuardi, F. Pavan, R. Cantón, 2021, bioRxiv.

The effects of Cannabidiol (CBD) and Delta-9-Tetrahydrocannabinol (THC) on the recognition of emotions in facial expressions: A systematic review of randomized controlled trials

C. Morgan, J. Crippa, J. Hallak, 2020, Neuroscience & Biobehavioral Reviews.

Effects of sodium nitroprusside in the prevention of schizophrenia-like symptoms induced by ketamine – A translational double-blind study

S. Dursun, R. Bressan, J. Hallak, 2017 .

Effect of two oral formulations of cannabidiol on responses to emotional stimuli in healthy human volunteers: pharmaceutical vehicle matters

F. Guimarães, J. Crippa, A. Zuardi, 2021, Revista brasileira de psiquiatria.

Adverse Effects of Oral Cannabidiol: An Updated Systematic Review of Randomized Controlled Trials (2020–2022)

F. Guimarães, A. Zuardi, Jaime E. C. Hallak, 2022, Pharmaceutics.

Maintained anxiolytic effects of cannabidiol after treatment discontinuation in healthcare workers during the COVID-19 pandemic

F. Guimarães, A. Zuardi, F. Kapczinski, 2022, Frontiers in Pharmacology.

Case Report: Cannabidiol-Induced Skin Rash: A Case Series and Key Recommendations

F. Guimarães, J. Crippa, A. Zuardi, 2022, Frontiers in Pharmacology.

Modulation of the Endocannabinoid and Oxytocinergic Systems as a Potential Treatment Approach for Social Anxiety Disorder

R. Martín-Santos, J. Hallak, J. Crippa, 2019, CNS Drugs.

Correction: Fluorinated Cannabidiol Derivatives: Enhancement of Activity in Mice Models Predictive of Anxiolytic, Antidepressant and Antipsychotic Effects

F. Guimarães, J. Crippa, A. Zuardi, 2016, PloS one.

Fluorinated Cannabidiol Derivatives: Enhancement of Activity in Mice Models Predictive of Anxiolytic, Antidepressant and Antipsychotic Effects

F. Guimarães, J. Crippa, A. Zuardi, 2016, PloS one.

Cortical thinning of the right anterior cingulate cortex in spider phobia: A magnetic resonance imaging and spectroscopy study

J. Sato, A. Jackowski, A. Nardi, 2014, Brain Research.

Cannabidiol Recovers Dopaminergic Neuronal Damage Induced by Reserpine or α-synuclein in Caenorhabditis elegans

S. Smaili, G. Pereira, C. Bincoletto, 2023, Neurochemical Research.

Cannabidiol Normalizes Caspase 3, Synaptophysin, and Mitochondrial Fission Protein DNM1L Expression Levels in Rats with Brain Iron Overload: Implications for Neuroprotection

N. Schröder, J. Hallak, A. Zuardi, 2013, Molecular Neurobiology.

Oxytocin does not improve performance of patients with schizophrenia and healthy volunteers in a facial emotion matching task

J. Hallak, A. Zuardi, M. H. Chagas, 2014, Psychiatry Research.

The size and prevalence of the cavum septum pellucidum are normal in subjects with panic disorder.

P. McGuire, D. Araujo, F. Guimarães, 2004, Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas.

Associations between primary health care strategies and outcomes of mental disorders

A. Zuardi, L. Moscovici, L. Bolsoni, 2020, Revista brasileira de psiquiatria.

Caffeine protects against memory loss induced by high and non-anxiolytic dose of cannabidiol in adult zebrafish (Danio rerio)

J. Hallak, J. Crippa, A. Zuardi, 2015, Pharmacology Biochemistry and Behavior.

Stability of the diagnosis of first-episode psychosis made in an emergency setting.

A. Zuardi, C. Del-Ben, R. Uchida, 2005, General hospital psychiatry.

Public psychiatric services: job satisfaction evaluation.

A. Zuardi, M. Bandeira, S. Ishara, 2007, Revista brasileira de psiquiatria.

Memory-rescuing effects of cannabidiol in an animal model of cognitive impairment relevant to neurodegenerative disorders

N. Schröder, J. Crippa, A. Zuardi, 2012, Psychopharmacology.

Cannabidiol Normalizes Caspase 3, Synaptophysin, and Mitochondrial Fission Protein DNM1L Expression Levels in Rats with Brain Iron Overload: Implications for Neuroprotection

N. Schröder, J. Hallak, J. Crippa, 2014, Molecular Neurobiology.

Cannabidiol and Neuroprotection: Evidence from Preclinical Studies

N. Schröder, A. Zuardi, J. Crippa, 2017 .

The Effect of Cannabidiol for Restless Legs Syndrome/Willis-Ekbom Disease in Parkinson's Disease Patients with REM Sleep Behavior Disorder: A Post Hoc Exploratory Analysis of Phase 2/3 Clinical Trial.

A. Zuardi, J. Crippa, A. Eckeli, 2022, Cannabis and cannabinoid research.

The anxiolytic effect of cannabidiol depends on the nature of the trauma when patients with post-traumatic stress disorder recall their trigger event

F. Guimarães, J. Crippa, J. Hallak, 2022, Revista brasileira de psiquiatria.

Effects of cannabidiol on symptoms induced by the recall of traumatic events in patients with posttraumatic stress disorder

F. Guimarães, J. Crippa, J. Hallak, 2022, Psychopharmacology.

Basic features of generalized anxiety disorder

A. Zuardi, 2017 .

Effect of image analysis software on neurofunctional activation during processing of emotional human faces

P. McGuire, P. Mcguire, P. Allen, 2010, Journal of Clinical Neuroscience.

Early interventions for the prevention of PTSD in adults: a systematic literature review

R. Martín-Santos, J. Crippa, A. Zuardi, 2017 .

Reliability and validity of the interactive observation scale for psychiatric inpatients applied by nursing aides in daily ward practice.

A. Zuardi, J. Hallak, L. J. Pedrão, 2001, Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas.

Social phobia in Brazilian university students: prevalence, under-recognition and academic impairment in women.

J. Crippa, A. Zuardi, F. Kapczinski, 2012, Journal of affective disorders.

A structured interview guide increases Brief Psychiatric Rating Scale reliability in raters with low clinical experience

J. Crippa, R. Sanches, A. Zuardi, 2001, Acta psychiatrica Scandinavica.

Short-Term Improvement by Minocycline Added to Olanzapine Antipsychotic Treatment in Paranoid Schizophrenia

S. Dursun, J. Hallak, A. Zuardi, 2009 .

Cannabinoids for the treatment of mental disorders.

F. Guimarães, J. Crippa, J. Hallak, 2020, The lancet. Psychiatry.

[Cannabis sativa: the plant that can induce unwanted effects and also treat them].

J. Hallak, J. Crippa, A. Zuardi, 2010, Revista brasileira de psiquiatria.

Minocycline and psychoneuroimmunology in schizophrenia

S. Dursun, J. Hallak, J. Crippa, 2010, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

P.1.e.025 Effects of the Amazonian psychoactive plant beverage ayahuasca on prefrontal and limbic regions during a language task: a fMRI study

J. Hallak, A. Zuardi, J. Crippa, 2009, European Neuropsychopharmacology.

Comparison between two models of experimental anxiety in healthy volunteers and panic disorder patients

F. Graeff, F. Guimarães, A. Zuardi, 2001, Neuroscience & Biobehavioral Reviews.

Do panic patients process unconditioned fear vs. conditioned anxiety differently than normal subjects?

F. Graeff, F. Guimarães, A. Zuardi, 2001, Psychiatry Research.

Cannabidiol Displays Proteomic Similarities to Antipsychotics in Cuprizone-Exposed Human Oligodendrocytic Cell Line MO3.13

D. Martins‐de‐Souza, J. Hallak, J. Crippa, 2021, Frontiers in Molecular Neuroscience.

Effects of tryptophan depletion on anxiety induced by simulated public speaking.

F. Graeff, F. Guimarães, A. Zuardi, 2000, Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas.

Complexidade do diagnostico diferencial em psiquiatria: relato de sindrome catatonica

A. Sakamoto, A. Zuardi, José Alexandre de Souza Crippa, 2001 .

Proton magnetic resonance spectroscopy of the frontal lobe in schizophrenics: a critical review of the methodology.

J. Hallak, J. Crippa, R. Sanches, 2004, Revista do Hospital das Clinicas.

Double-blind comparison between two forms of haloperidol: an oral preparation and a new depot decanoate in the maintenance of schizophrenic inpatients

A. Zuardi, A. Giampietro, I. G. Karniol, 1983 .

Factor structure of Bech's version of the Brief Psychiatric Rating Scale in Brazilian patients.

J. Crippa, R. Sanches, A. Zuardi, 2002, Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas.

The Effects of Sodium Nitroprusside Treatment on Cognitive Deficits in Schizophrenia: A Pilot Study

S. Dursun, J. Hallak, J. Crippa, 2015, Journal of clinical psychopharmacology.

Cannabidiol modulates chronic neuropathic pain aversion behavior by attenuation of neuroinflammation markers and neuronal activity in the corticolimbic circuit in male Wistar rats

A. Zuardi, N. Garcia-Cairasco, Jaime E. C. Hallak, 2023, Behavioural Brain Research.

Social anxiety disorder: what are we losing with the current diagnostic criteria?

L. Hetem, J. Crippa, A. Zuardi, 2010, Acta psychiatrica Scandinavica.

Pharmacological interventions during the process of reconsolidation of aversive memories: A systematic review

A. Zuardi, L. Bolsoni, 2019, Neurobiology of Stress.

Pharmacological Interaction Between Cannabidiol and Tramadol on Experimental Diabetic Neuropathic Pain: An Isobolographic Analysis.

J. Hallak, A. Zuardi, J. M. Cunha, 2023, Cannabis and cannabinoid research.

Mental health trajectories of Brazilian health workers during two waves of the COVID-19 pandemic (2020–2021)

J. Hallak, A. Zuardi, F. de Lima Osório, 2023, Frontiers in Psychiatry.

Effect of chlorimipramine and maprotiline on experimental anxiety in humans

F. Graeff, F. Guimarães, A. Zuardi, 1987, Journal of psychopharmacology.

Monitoring the Mental Health and Professional Overload of Health Workers in Brazil: A Longitudinal Study Considering the First Wave of the COVID-19 Pandemic

J. Crippa, J. Hallak, A. Zuardi, 2022, Frontiers in Psychiatry.

Does the "Entourage Effect" in Cannabinoids Exist? A Narrative Scoping Review.

F. Guimarães, A. Zuardi, A. Campos, 2023, Cannabis and cannabinoid research.

Integrated mental healthcare: outcomes from Brazilian primary care

A. Zuardi, L. Moscovici, J. M. Azevedo-Marques, 2016 .

Specific mental disorder screening compilation may detect general mental disorders

A. Zuardi, L. Moscovici, L. Bolsoni, 2018 .

No association between electrodermal hyporesponsivity and enlarged cavum septi pellucidi in schizophrenia

P. McGuire, G. Busatto, J. Crippa, 2007, Schizophrenia Research.

[Social performance expectations in psychiatric patients of a general hospital ward].

J. Crippa, A. Zuardi, M. S. Moreira, 2002, Revista de saude publica.

Cannabidiol for the treatment of psychosis in Parkinson’s disease

S. Dursun, J. Hallak, A. Zuardi, 2009, Journal of psychopharmacology.

The role of inflammation in schizophrenia: an overview.

J. Hallak, A. Zuardi, C. Chaves, 2015, Trends in psychiatry and psychotherapy.

Agomelatine in the treatment of social anxiety disorder

A. Nardi, J. Crippa, J. Hallak, 2010, Progress in Neuro-psychopharmacology and Biological Psychiatry.

Dr. Raphael Mechoulam, cannabis and cannabinoids research pioneer (November 5, 1930–March 9, 2023) and his legacy for Brazilian pharmacology

F. Guimarães, J. Hallak, A. Zuardi, 2023, Revista brasileira de psiquiatria.

Human experimental anxiety: actual public speaking induces more intense physiological responses than simulated public speaking.

J. Hallak, J. Crippa, A. Zuardi, 2013, Revista brasileira de psiquiatria.

D-fenfluramine reduces anxiety induced by simulated public speaking.

F. Graeff, F. Guimarães, A. Zuardi, 1993, Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas.

Cannabidiol administration reduces the expression of genes involved in mitochondrial electron transport chain and ribosome biogenesis in mice CA1 neurons

A. Zuardi, Jaime E. C. Hallak, Valéria de Almeida, 2023, bioRxiv.

Acute harmine administration induces antidepressive-like effects and increases BDNF levels in the rat hippocampus

G. Réus, J. Quevedo, J. Hallak, 2009, Progress in Neuro-psychopharmacology and Biological Psychiatry.

P.1.j.006 Involvement of the prelimbic cortex in the disruptive effect of cannabidiol on fear memory reconsolidation

A. Zuardi, F. S. Guimarães, C. Stern, 2014, European Neuropsychopharmacology.

Antidepressant-like and anxiolytic-like effects of cannabidiol: a chemical compound of Cannabis sativa.

S. Machado, A. Nardi, J. Crippa, 2014, CNS & neurological disorders drug targets.

Cannabidiol Reduces the Anxiety Induced by Simulated Public Speaking in Treatment-Naïve Social Phobia Patients

R. Roesler, J. Quevedo, R. Martín-Santos, 2011, Neuropsychopharmacology.

Effects of ipsapirone and cannabidiol on human experimental anxiety

F. Graeff, A. Zuardi, R. Cosme, 1993, Journal of psychopharmacology.

Is cannabidiol the ideal drug to treat non-motor Parkinson’s disease symptoms?

F. Guimarães, J. Crippa, J. Hallak, 2019, European Archives of Psychiatry and Clinical Neuroscience.

Progression of the COVID-19 pandemic, Brazilian healthcare workers’ emotional burden and the effects on professional fulfillment at the end of the third wave: a longitudinal study

A. Zuardi, S. Loureiro, J. Hallak, 2023, Frontiers in Psychiatry.

Mitral valve prolapse and anxiety disorders

Clarissa Trzesniak, B. Maciel, A. Nardi, 2011, British Journal of Psychiatry.

Psychometric properties of the Fagerström Test for Nicotine Dependence.

J. Crippa, A. Zuardi, S. Loureiro, 2009, Jornal brasileiro de pneumologia : publicacao oficial da Sociedade Brasileira de Pneumologia e Tisilogia.

Neuroimaging studies of acute effects of THC and CBD in humans and animals: a systematic review.

P. McGuire, F. Guimarães, G. Busatto, 2014, Current pharmaceutical design.

Harmine impairs memory performance of treated rats and nontreated cagemates.

A. Zuardi, R. Silva, Jaime E. C. Hallak, 2021, Experimental and clinical psychopharmacology.

Total agenesis of the corpus callosum in a patient with childhood-onset schizophrenia

J. Deakin, S. Dursun, A. Zuardi, 2003, Schizophrenia Research.

1H magnetic resonance spectroscopy imaging of the hippocampus in patients with panic disorder

A. C. Santos, F. Graeff, F. Guimarães, 2010, Psychiatry Research: Neuroimaging.

Task-independent acute effects of delta-9-tetrahydrocannabinol on human brain function and its relationship with cannabinoid receptor gene expression: A neuroimaging meta-regression analysis

N. Ramsey, M. Veronese, J. Raduà, 2022, Neuroscience & Biobehavioral Reviews.

Task-independent Acute Effects of delta-9-tetrahydrocannabinol on Human Brain Function and Its Relationship With Cannabinoid Receptor Gene Expression_ A Neuroimaging Meta-regression AnalysisShort title_ Acute effects of THC on the human brain

M. Veronese, S. Bhattacharyya, M. Bossong, 2022 .

Olanzapine for Recurrent Aggression in a Patient with Temporal Lobe Epilepsy who had Temporal Lobectomy

J. Deakin, S. Dursun, A. Sakamoto, 2003, Journal of psychopharmacology.

P.5.d.002 Cannabidiol add-on usual treatment improves the outcome of patients with Parkinson's disease

A. Zuardi, J. Crippa, A. Eckeli, 2013, European Neuropsychopharmacology.

Cannabis affects people differently: inter-subject variation in the psychotogenic effects of Δ9-tetrahydrocannabinol: a functional magnetic resonance imaging study with healthy volunteers

P. Allen, D. Ståhl, S. Borgwardt, 2012, Psychological Medicine.

Cannabidiol modulates hippocampal genes involved in mitochondrial function, ribosome biogenesis, synapse organization, and chromatin modifications.

A. Zuardi, Jaime E. C. Hallak, Valéria de Almeida, 2024, Acta neuropsychiatrica.

Cannabidiol as an Adjunctive Treatment for Acute Bipolar Depression: A Pilot Study: Le cannabidiol comme traitement d'appoint de la dépression bipolaire aiguë : une étude pilote

A. Zuardi, L. Yatham, K. Ceresér, 2023, Canadian journal of psychiatry. Revue canadienne de psychiatrie.